The epidemiology, clinical manifestations, and management of chagas heart disease

Clinical Cardiology

Volumn 38, Issue 9, 2015, Pages 565-569

  Malik, Lindsey H ^a   Singh, Gagan D ^a   Amsterdam, Ezra A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; BENZNIDAZOLE; IMMUNOGLOBULIN G; INSECTICIDE; NIFURTIMOX; PLACEBO; POSACONAZOLE; ANTIPARASITIC AGENT; CARDIOVASCULAR AGENT;

ANTIBODY DETECTION; BLOOD TRANSFUSION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CHAGAS DISEASE; CLINICAL FEATURE; CONGENITAL INFECTION; DEFIBRILLATION; DISEASE TRANSMISSION; ENDEMIC DISEASE; ENVIRONMENTAL SANITATION; FECES; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFECTION CONTROL; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MICROBIAL CONTAMINATION; MORTALITY; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PATIENT CARE; PERICARDITIS; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; SEROLOGY; SOUTH AND CENTRAL AMERICA; THROMBOEMBOLISM; TRYPANOSOMA CRUZI; UNSPECIFIED SIDE EFFECT; WESTERN HEMISPHERE; CARDIOVERSION; CHAGAS CARDIOMYOPATHY; DEVICES; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PARASITOLOGY; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

ANTIPARASITIC AGENTS; CARDIOVASCULAR AGENTS; CHAGAS CARDIOMYOPATHY; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84942820047     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22421     Document Type: Review

References (38)

1. Schofield CJ, Dias JC,. A cost-benefit analysis of Chagas disease control. Mem Inst Oswaldo Cruz. 1991; 86: 285-295.
2. Centers for Disease Control and Prevention. Parasites-American trypanosomiasis (also known as Chagas Disease). http://www.cdc.gov/parasites/Chagas. Accessed May 1, 2014.
3. Traina M, Sanchez D, Hernandez S, et al., Chagasic cardiomyopathy is associated with increased morbidity and mortality compared with nonischemic cardiomyopathy among Latin American immigrants in Los Angeles. Circulation. 2012; 126:A18171.
4. Bern C, Montgomery S,. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009; 49: e52-e54.
5. Schmunis G., Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007; 102 (suppl 1): 75-85.
6. Rossi M, Ramos S, Bestetti R,. Chagas' heart disease: clinical-pathological correlation. Front Biosci. 2003; 8: e94-e109.
7. Shikanai-Yasuda M, Carvalho N,. Oral transmission of Chagas disease. Clin Infect Dis. 2012; 54: 845-852.
8. Rassi A Jr, Rassi A, Marin-Neto J,. Chagas disease. Lancet. 2010; 375: 1388-1402.
9. Andrade Z, Andrade S, Sadigursky M, et al., The indeterminate phase of Chagas' disease: ultrastructural characterization of cardiac changes in the canine model. Am J Trop Med Hyg. 1997; 57: 328-336.
10. Rossi M., Patterns of myocardial fibrosis in idiopathic cardiomyopathies and chronic Chagasic cardiopathy. Can J Cardiol. 1991; 7: 287-294.
11. Alvarado-Tapias E, Miranda-Pacheco R, Rodríguez-Bonfante C, et al., Electrocardiography repolarization abnormalities are characteristic signs of acute Chagasic cardiomyopathy. Invest Clin. 2012; 53: 378-394.
12. Ribeiro A, Nunes M, Teixeira M, et al., Diagnosis and management of Chagas disease cardiomyopathy. Nat Rev Cardiol. 2012; 9: 576-589.
13. Williams-Blangero S, Magalhaes T, Rainwater E, et al., Electrocardiographic characteristics in a population with high rates of seropositivity for Trypanosoma cruzi infection. Am J Trop Med Hyg. 2007; 77: 495-499.
14. Dias J., The indeterminate form of human chronic Chagas' disease. A clinical epidemiological review. Rev Soc Bras Med Trop. 1989; 22: 147-156.
15. Molina R, Matsubara B, Hueb J, et al., Dysautonomia and ventricular dysfunction in the indeterminate form of Chagas disease. Int J Cardiol. 2006; 113: 188-193.
16. Regueiro A, Garcia-Alvarez A, Sitges M, et al., Myocardial involvement in Chagas disease: insights from cardiac magnetic resonance. Int J Cardiol. 2013; 165: 107-112.
17. Rassi A Jr, Rassi S, Rassi A,. Sudden death in Chagas' disease. Arq Bras Cardiol. 2001; 76: 75-96.
18. Rassi A Jr, Waktare J, Rassi SG, et al., Chagas heart disease: long term prognostic significance of nonsustained ventricular tachycardia and left ventricular dysfunction. Pacing Clin Electrophysiol. 1999; 22 (part II):862.
19. Maguire J, Hoff R, Sherlock I, et al., Cardiac morbidity and mortality due to Chagas disease: prospective electrocardiographic study of a Brazilian community. Circulation. 1987; 75: 1140-1145.
20. Acquatella H., Echocardiography in Chagas heart disease. Circulation. 2007; 115: 1124-1131.
21. Perez-Molina J, Perez-Ayala A, Moreno S, et al., Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta analysis. J Antimicrob Chemother. 2009; 64: 1139-1147.
22. Marin-Neto J, Rassi A Jr, Avezum A Jr, et al., The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009; 104 (suppl 1): 319-324.
23. Bern C., Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med. 2011; 364: 2527-2534.
24. Molina I, Prat J, Salvador F, et al., Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med. 2014; 370: 1899-1908.
25. Yancy C, Jessup M, Butler J, et al., 2013 ACCF/AHA. Guideline for the management of Heart Failure. J Am Coll Cardiol. 2013; 62: e147-e239.
26. Roberti R, Martinez E, Andrade A, et al., Chagas cardiomyopathy and captopril. Eur Heart J. 1992; 13: 966-970.
27. Botoni F, Poole-Wilson P, Ribeiro A, et al., A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J. 2007; 153:544.e1-e8.
28. Bestetti R, Otaviano A, Cardinalli-Neto A, et al., Effects of b-blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure. Int J Cardiol. 2001; 151: 205-208.
29. Quiros F, Morillo C, Casas J, et al., CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy. Trials. 2006; 7: 21
30. Bestetti R, Muccillo G,. Clinical course of Chagas heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol. 1997; 60: 187-193.
31. Braga J, Reis F, Aras R, et al., Clinical and therapeutic aspects of heart failure due to Chagas disease. Arq Bras Cardiol. 2006; 86: 297-302.
32. Aruajo E, Chamlian E, Peroni A, et al., Cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy: long-term follow up. Rev Bras Cir Cardiovasc. 2014; 29: 31-36.
33. Benaim G, Sanders J, Garcia-Marchan Y, et al., Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem. 2006; 49: 892-899.
34. Pereira F, Rocha E, Monteiro Mde P, et al., Long-term follow-up of patients with chronic Chagas disease and implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2014; 37: 751-756.
35. Gali W, Sarabanda A, Baggio A, et al., Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone. Europace. 2014; 16: 674-680.
36. Epstein A, DiMarco J, Ellenbogen K, et al., ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008; 117: e350-e408.
37. Arce M, VAN Grieken J, Femenia F, et al., Permanent pacing in patients with Chagas' disease. Pacing Clin Electrophysiol 2012; 35: 1494-1497.
38. Traina M, Sanchez D, Hernandez S, et al., Chagasic cardiomyopathy is associated with increased morbidity and mortality compared with nonischemic cardiomyopathy among Latin American immigrants in Los Angeles. Circulation. 2012; 126:A18171